Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
crispr
5
×
life sciences
national blog main
national top stories
san francisco blog main
san francisco top stories
gene editing
biotech
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
glaxosmithkline
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
celgene
clinical study
commissioner
congress
deals
democrats
eli lilly
failure
gene therapy
indiana blog main
indiana top stories
What
bio
5
×
crispr
5
×
roundup
big
cas
new
years
allogene
available
based
biopharma
biosciences
bosley's
bosley’s
bridge
bucks
cancer
ceo
cheaper
congress
congressional
create
crime
departure
develop
diagnostic
diagnostics
diseases
diversity
editas
editing
executives
exit
expects
faster
feud
fix
gene
group
guiding
Language
unset
Current search:
crispr
×
bio
×
crispr
×
@xconomy.com
4 years ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com
5 years ago
CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
